
NICE issues draft guidance rejecting Abbvie’s Venclyxto in chronic lymphocytic leukaemia
pharmafile | October 26, 2018 | News story | Medical Communications, Sales and Marketing | AbbVie, NHS, NICE, leukaemia, pharma, venetoclax
It’s bad news for patients in the UK affected by chronic lymphocytic leukaemia (CLL) as the National Institute of Health and Care Excellence (NICE) has announced its decision not to recommend Abbvie’s Venclyxto (venetoclax) in combination with Genentech’s Rituxan (rituximab) for use on the NHS in the treatment of relapsed or refractory forms of the disease in adults, with the publication of its draft guidance.
NICE’s guidance states that clinical evidence supports the ability of the combo to extend progression-free survival compared to the now-rarely used combo of bendamustine plus rituximab, but no firm conclusions can be drawn between its efficacy and standard of care ibrutinib with rituximab, so the benefits cannot be accurately ascertained. Thus, the organisation cannot make a solid call on the combo’s cost-effectiveness.
Taken orally once daily with a gradually increasing dose from 20mg to 400mg over the first 5 weeks of treatment, the list price for a 112-pack of venetoclax stands at £4,789.47.
CLL is one of the most common forms of leukaemia, and rarely affects those under the age of 40. There are around 3,500 new cases of the condition each year in the UK, with 1,008 CLL-related deaths recorded in 2016.
The organisation has passed its draft guidance onto stakeholders and is inviting comments on the decision until 16 November.
Matt Fellows
Related Content

Digital mental health technologies – a valuable tool in supporting people with depression and anxiety
The potential benefits of digital mental health technology for managing depression, anxiety and stress, together …

A community-first future: which pathways will get us there?
In the final Gateway to Local Adoption article of 2025, Visions4Health caught up with Julian …

The Pharma Files: with Dr Ewen Cameron, Chief Executive of West Suffolk NHS Foundation Trust
Pharmafile chats with Dr Ewen Cameron, Chief Executive of West Suffolk NHS Foundation Trust, about …






